166 related articles for article (PubMed ID: 15177482)
21. 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.
Lumeras W; Vidal L; Vidal B; Balagué C; Orellana A; Maldonado M; Domínguez M; Segarra V; Caturla F
J Med Chem; 2011 Nov; 54(22):7899-910. PubMed ID: 21999461
[TBL] [Abstract][Full Text] [Related]
22. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.
de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA
J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819
[TBL] [Abstract][Full Text] [Related]
23. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
[TBL] [Abstract][Full Text] [Related]
24. Pyridinylimidazole based p38 MAP kinase inhibitors.
Jackson PF; Bullington JL
Curr Top Med Chem; 2002 Sep; 2(9):1011-20. PubMed ID: 12171568
[TBL] [Abstract][Full Text] [Related]
25. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: exploration of effective compounds in arthritis models.
Shimizu H; Yamasaki T; Yoneda Y; Muro F; Hamada T; Yasukochi T; Tanaka S; Toki T; Yokoyama M; Morishita K; Iimura S
Bioorg Med Chem Lett; 2011 Aug; 21(15):4550-5. PubMed ID: 21705219
[TBL] [Abstract][Full Text] [Related]
26. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
27. The development of monocyclic pyrazolone based cytokine synthesis inhibitors.
Golebiowski A; Townes JA; Laufersweiler MJ; Brugel TA; Clark MP; Clark CM; Djung JF; Laughlin SK; Sabat MP; Bookland RG; VanRens JC; De B; Hsieh LC; Janusz MJ; Walter RL; Webster ME; Mekel MJ
Bioorg Med Chem Lett; 2005 May; 15(9):2285-9. PubMed ID: 15837310
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
[TBL] [Abstract][Full Text] [Related]
29. SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.
Revesz L; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Wolf R; Zimmerlin AG
Bioorg Med Chem Lett; 2002 Aug; 12(16):2109-12. PubMed ID: 12127515
[TBL] [Abstract][Full Text] [Related]
30. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy.
Mclay LM; Halley F; Souness JE; McKenna J; Benning V; Birrell M; Burton B; Belvisi M; Collis A; Constan A; Foster M; Hele D; Jayyosi Z; Kelley M; Maslen C; Miller G; Ouldelhkim MC; Page K; Phipps S; Pollock K; Porter B; Ratcliffe AJ; Redford EJ; Webber S; Slater B; Thybaud V; Wilsher N
Bioorg Med Chem; 2001 Feb; 9(2):537-54. PubMed ID: 11249145
[TBL] [Abstract][Full Text] [Related]
31. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
[TBL] [Abstract][Full Text] [Related]
32. Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitors.
Koch P; Laufer S
J Med Chem; 2010 Jun; 53(12):4798-802. PubMed ID: 20481631
[TBL] [Abstract][Full Text] [Related]
33. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
[TBL] [Abstract][Full Text] [Related]
34. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of unactivated p38 MAP kinase.
Bullington J; Argentieri D; Averill K; Carter D; Cavender D; Fahmy B; Fan X; Hall D; Heintzelman G; Jackson P; Leung WP; Li X; Ling P; Olini G; Razler T; Reuman M; Rupert K; Russell R; Siekierka J; Wadsworth S; Wolff R; Xiang B; Zhang YM
Bioorg Med Chem Lett; 2006 Dec; 16(23):6102-6. PubMed ID: 16971122
[TBL] [Abstract][Full Text] [Related]
37. Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis.
Dyckman AJ; Langevine CM; Quesnelle C; Kempson J; Guo J; Gill P; Spergel SH; Watterson SH; Li T; Nirschl DS; Gillooly KM; Pattoli MA; McIntyre KW; Chen L; McKinnon M; Dodd JH; Barrish JC; Burke JR; Pitts WJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):383-6. PubMed ID: 21087862
[TBL] [Abstract][Full Text] [Related]
38. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha.
Mihara K; Almansa C; Smeets RL; Loomans EE; Dulos J; Vink PM; Rooseboom M; Kreutzer H; Cavalcanti F; Boots AM; Nelissen RL
Br J Pharmacol; 2008 May; 154(1):153-64. PubMed ID: 18297096
[TBL] [Abstract][Full Text] [Related]
39. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
Anderson DR; Meyers MJ; Vernier WF; Mahoney MW; Kurumbail RG; Caspers N; Poda GI; Schindler JF; Reitz DB; Mourey RJ
J Med Chem; 2007 May; 50(11):2647-54. PubMed ID: 17480064
[TBL] [Abstract][Full Text] [Related]
40. A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.
Mbalaviele G; Sommers CD; Bonar SL; Mathialagan S; Schindler JF; Guzova JA; Shaffer AF; Melton MA; Christine LJ; Tripp CS; Chiang PC; Thompson DC; Hu Y; Kishore N
J Pharmacol Exp Ther; 2009 Apr; 329(1):14-25. PubMed ID: 19168710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
